Barrett's esophagus: Surveillance and treatment

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Barrett's esophagus is a disease of paramount importance dictated by its exponentially increasing incidence and association with esophageal cancer. Unfortunately, our knowledge lacks much of the key data and information to make those important decisions in Barrett's as regards screening and treatment. With an evident lack of long-term large population studies of patients with Barrett's esophagus, much of our decision making is based on little available data and becomes somewhat arbitrary. Given these limitations, screening criteria include adults with a long history of persistent reflux symptoms. The precise age, frequency, and duration of symptoms used is unclear. Once Barrett's is identified, endoscopic surveillance is performed every 2 years, but this interval will most likely lengthen to 3 years. For patients with LGD, surveillance every 6-12 months is recommended. For HGD, esophagectomy is still recommended for healthy surgical candidates, but more patients will be followed, particularly those with "focal" HGD. The role of acid suppression either pharmacologically or surgically is not clear, but the tendency is to achieve near complete control of the acid reflux. Endoscopic ablative procedures are experimental and may be indicated in patients at high surgical risk with HGD and carcinoma. Its role in mainstream practice is yet to be defined.

Original languageEnglish (US)
Pages (from-to)481-497
Number of pages17
JournalGastroenterology Clinics of North America
Volume31
Issue number2
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Barrett Esophagus
Acids
Esophagectomy
Therapeutics
Esophageal Neoplasms
Decision Making
Carcinoma
Incidence
Population

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Barrett's esophagus : Surveillance and treatment. / Katzka, David A.

In: Gastroenterology Clinics of North America, Vol. 31, No. 2, 2002, p. 481-497.

Research output: Contribution to journalArticle

@article{3abc6295ecf1467b9ac0443b35dba03f,
title = "Barrett's esophagus: Surveillance and treatment",
abstract = "Barrett's esophagus is a disease of paramount importance dictated by its exponentially increasing incidence and association with esophageal cancer. Unfortunately, our knowledge lacks much of the key data and information to make those important decisions in Barrett's as regards screening and treatment. With an evident lack of long-term large population studies of patients with Barrett's esophagus, much of our decision making is based on little available data and becomes somewhat arbitrary. Given these limitations, screening criteria include adults with a long history of persistent reflux symptoms. The precise age, frequency, and duration of symptoms used is unclear. Once Barrett's is identified, endoscopic surveillance is performed every 2 years, but this interval will most likely lengthen to 3 years. For patients with LGD, surveillance every 6-12 months is recommended. For HGD, esophagectomy is still recommended for healthy surgical candidates, but more patients will be followed, particularly those with {"}focal{"} HGD. The role of acid suppression either pharmacologically or surgically is not clear, but the tendency is to achieve near complete control of the acid reflux. Endoscopic ablative procedures are experimental and may be indicated in patients at high surgical risk with HGD and carcinoma. Its role in mainstream practice is yet to be defined.",
author = "Katzka, {David A}",
year = "2002",
doi = "10.1016/S0889-8553(02)00020-1",
language = "English (US)",
volume = "31",
pages = "481--497",
journal = "Gastroenterology Clinics of North America",
issn = "0889-8553",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Barrett's esophagus

T2 - Surveillance and treatment

AU - Katzka, David A

PY - 2002

Y1 - 2002

N2 - Barrett's esophagus is a disease of paramount importance dictated by its exponentially increasing incidence and association with esophageal cancer. Unfortunately, our knowledge lacks much of the key data and information to make those important decisions in Barrett's as regards screening and treatment. With an evident lack of long-term large population studies of patients with Barrett's esophagus, much of our decision making is based on little available data and becomes somewhat arbitrary. Given these limitations, screening criteria include adults with a long history of persistent reflux symptoms. The precise age, frequency, and duration of symptoms used is unclear. Once Barrett's is identified, endoscopic surveillance is performed every 2 years, but this interval will most likely lengthen to 3 years. For patients with LGD, surveillance every 6-12 months is recommended. For HGD, esophagectomy is still recommended for healthy surgical candidates, but more patients will be followed, particularly those with "focal" HGD. The role of acid suppression either pharmacologically or surgically is not clear, but the tendency is to achieve near complete control of the acid reflux. Endoscopic ablative procedures are experimental and may be indicated in patients at high surgical risk with HGD and carcinoma. Its role in mainstream practice is yet to be defined.

AB - Barrett's esophagus is a disease of paramount importance dictated by its exponentially increasing incidence and association with esophageal cancer. Unfortunately, our knowledge lacks much of the key data and information to make those important decisions in Barrett's as regards screening and treatment. With an evident lack of long-term large population studies of patients with Barrett's esophagus, much of our decision making is based on little available data and becomes somewhat arbitrary. Given these limitations, screening criteria include adults with a long history of persistent reflux symptoms. The precise age, frequency, and duration of symptoms used is unclear. Once Barrett's is identified, endoscopic surveillance is performed every 2 years, but this interval will most likely lengthen to 3 years. For patients with LGD, surveillance every 6-12 months is recommended. For HGD, esophagectomy is still recommended for healthy surgical candidates, but more patients will be followed, particularly those with "focal" HGD. The role of acid suppression either pharmacologically or surgically is not clear, but the tendency is to achieve near complete control of the acid reflux. Endoscopic ablative procedures are experimental and may be indicated in patients at high surgical risk with HGD and carcinoma. Its role in mainstream practice is yet to be defined.

UR - http://www.scopus.com/inward/record.url?scp=0035992165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035992165&partnerID=8YFLogxK

U2 - 10.1016/S0889-8553(02)00020-1

DO - 10.1016/S0889-8553(02)00020-1

M3 - Article

C2 - 12134614

AN - SCOPUS:0035992165

VL - 31

SP - 481

EP - 497

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

SN - 0889-8553

IS - 2

ER -